Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 10Lymphoid 5Thoracic 2Dermatologic 2Sarcoma 1Plasma cell 1Myeloid 1Head & Neck 1Genitourinary 1Classical hematology 1Breast 1

Conditions

Sarcoma 160Glioblastoma 86Gliosarcoma 79Brain Neoplasms 52Central Nervous System Neoplasms 47Osteosarcoma 43Astrocytoma 40Sarcoma, Ewing 39Neoplasm Metastasis 37Melanoma 35Rhabdomyosarcoma 34Neoplasms 34Ovarian Neoplasms 33Glioma 32Neuroblastoma 30Breast Neoplasms 30Oligodendroglioma 29Lymphoma 28Recurrence 27Colorectal Neoplasms 26Carcinoma, Non-Small-Cell Lung 25Dendritic Cell Sarcoma, Interdigitating 22Stomach Neoplasms 21Lymphoma, Non-Hodgkin 21Gastrointestinal Stromal Tumors 20Carcinoma, Renal Cell 19Sarcoma, Synovial 18Pancreatic Neoplasms 18Lymphoma, Follicular 18Neurofibrosarcoma 17

Interventions

Cyclophosphamide 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasm, Residual × Sarcoma × Clear all
NCT02054104 2022-01-26

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
21 enrolled 11 charts
DermatologicSarcoma

Melanoma, Sarcoma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡